ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.35% Direct Plan: 0.47%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 19 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	230.79
AAUM (in Rs. Cr):	223.37
% of top 5 holdings:	36.55%
% of top 10 holdings:	54.86%
No. of scrips:	40

Standard Deviation^:	15.01%
Beta^:	0.86
*Sharpe Ratio^:**	0.81
Average P/B	10.04
Average P/E	49.92
Portfolio Turnover Ratio	0.59
^Computed for the 3-yr period ended December 31, 2024. Based on monthly return. * Risk free rate: 7.15 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	17.4284	18.5961
IDCW:	17.4284	18.5961

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	98.91
Chemicals	1.77
Sumitomo Chemical India Limited	1.13
Linde India Limited	0.63
Financial Services	1.32
HDFC Life Insurance Company Limited	1.32
Healthcare	95.82
Sun Pharmaceutical Industries Limited	15.23
Lupin Limited	6.53
Divi's Laboratories Limited	5.02
Aurobindo Pharma Limited	4.94
Suven Pharmaceuticals Limited	4.84
Apollo Hospitals Enterprise Limited	4.80
Max Healthcare Institute Limited	3.84
Torrent Pharmaceuticals Limited	3.53
Laurus Labs Limited	3.21
Dr. Reddy's Laboratories Limited	2.93
Alkem Laboratories Limited	2.47
Aster DM Healthcare Limited	2.47
Syngene International Limited	2.33
Orchid Pharma Limited	2.20
Mankind Pharma Limited	2.15
Granules India Limited	2.15
Piramal Pharma Limited	1.91
Neuland Laboratories Limited	1.70
Caplin Point Laboratories Limited	1.60
Ajanta Pharma Limited	1.49
IPCA Laboratories Limited	1.44
Shilpa Medicare Limited	1.44
Healthcare Global Enterprises Limited	1.44
Wockhardt Limited	1.44
Fortis Healthcare Limited	1.40
FDC Limited	1.39
Vijaya Diagnostic Centre Limited	1.38
Emcure Pharmaceuticals Limited	1.30
Supriya Lifescience Limited	1.28
Gland Pharma Limited	1.27
Yatharth Hospital And Trauma Care Services Limited	1.24
Rainbow Childrens Medicare Limited	1.04
Cipla Limited	1.02
GlaxoSmithKline Pharmaceuticals Limited	1.01
Onesource Specialty Pharma Limited	1.00
Strides Pharma Science Limited	0.79
Sai Life Sciences Limited	0.61
Short Term Debt & Net Current Assets	1.09

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	40.85%	40.96%	10.00%	14,125	14,136	11,009
Last 3 Years	19.27%	19.39%	12.16%	16,977	17,025	14,114
Since Inception	19.30%	19.86%	10.18%	17,428	17,687	13,567
Direct - Growth
Last 1 Year	43.52%	40.96%	10.00%	14,395	14,136	11,009
Last 3 Years	21.74%	19.39%	12.16%	18,053	17,025	14,114
Since Inception	21.78%	19.86%	10.18%	18,596	17,687	13,567

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10. Since the scheme is in existence for more than 3 years but less than 5 years hence performance data for 5 years and more are not provided.
ITI Pharma & Healthcare Fund NAV as on December 31, 2024: Rs. 17.4284 (Regular Growth Option), Rs. 18.5961 (Direct Growth Option)

Period	Amount Invested	Fund Value ()	Fund Returns (%)	Benchmark Value ()	Benchmark Returns (%)	Additional Benchmark Value ()	Additional Benchmark Returns (%)
Regular - Growth
Last 1 Year	1,20,000	1,43,919	38.89%	1,41,678	35.09%	1,21,600	2.48%
Last 3 Years	3,60,000	5,76,325	33.05%	5,74,847	32.85%	4,45,453	14.32%
Since Inception	3,80,000	6,11,559	31.50%	6,10,230	31.34%	4,73,292	13.97%
Direct - Growth
Last 1 Year	1,20,000	1,45,462	41.53%	1,41,678	35.09%	1,21,600	2.48%
Last 3 Years	3,60,000	5,95,950	35.60%	5,74,847	32.85%	4,45,453	14.32%
Since Inception	3,80,000	6,33,516	34.02%	6,10,230	31.34%	4,73,292	13.97%

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).